Phase 1 clinical trial of CUDC-101 ‘throws kitchen sink’ at head and neck cancer

26 enero 2015

At 18 months median follow up of a phase 1 clinical trial, one patient’s cancer had worsened, two had died, and nine remained free of disease. Testing of blood and tumor samples showed that CUDC-101 had indeed inhibited the action of EGFR, HDAC and Her2.